Total Payments
$551,260
2023 Payments
$148,669
Companies
4
Transactions
74
Payment Breakdown by Category
Research$546,341 (99.1%)
Travel$3,532 (0.6%)
Food & Beverage$1,387 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $546,341 | 30 | 99.1% |
| Travel and Lodging | $3,532 | 13 | 0.6% |
| Food and Beverage | $1,387 | 31 | 0.3% |
Payments by Type
Research
$546,341
30 transactions
General
$4,919
44 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ascensia Diabetes Care US Inc. | $292,421 | 7 | $0 (2020) |
| Eli Lilly and Company | $256,710 | 61 | $0 (2023) |
| PFIZER INC. | $1,339 | 5 | $0 (2019) |
| Eli Lilly Export S.A. Puerto Rico Branch | $790.46 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $148,669 | 4 | Eli Lilly and Company ($148,669) |
| 2022 | $3,171 | 4 | Eli Lilly and Company ($3,171) |
| 2020 | $302,086 | 40 | Ascensia Diabetes Care US Inc. ($292,410) |
| 2019 | $1,339 | 5 | PFIZER INC. ($1,339) |
| 2018 | $66,546 | 13 | Eli Lilly and Company ($66,535) |
| 2017 | $29,450 | 8 | Eli Lilly and Company ($29,450) |
All Payment Transactions
74 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $99.32 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | ||||||
| 04/28/2023 | Eli Lilly and Company | — | — | In-kind items and services | $49.59 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | ||||||
| 02/21/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $148,089.00 | Research |
| 01/10/2023 | Eli Lilly and Company | — | — | In-kind items and services | $430.65 | Research |
| Study: A PHASE 3 MULTICENTER RANDOMIZED PARALLEL-DESIGN OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $386.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | ||||||
| 04/08/2022 | Eli Lilly and Company | — | — | In-kind items and services | $1,407.00 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) | ||||||
| 04/08/2022 | Eli Lilly and Company | — | — | In-kind items and services | $1,078.00 | Research |
| Study: A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO IN PARTICIPANTS WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES | ||||||
| 04/08/2022 | Eli Lilly and Company | — | — | In-kind items and services | $300.00 | Research |
| Study: A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | ||||||
| 12/17/2020 | Eli Lilly and Company | — | — | In-kind items and services | $1,703.73 | Research |
| Study: RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | ||||||
| 11/25/2020 | Ascensia Diabetes Care US Inc. | — | — | Cash or cash equivalent | $85,570.00 | Research |
| Study: Clinical Trial Agreement - CTX - GCA-PRO-2020-004-01 | ||||||
| 10/27/2020 | Eli Lilly and Company | — | — | In-kind items and services | $603.06 | Research |
| Study: A STUDY OF LY900014 IN PARTICIPANTS WITH TYPE 2 DIABETES USING CONTINUOUS GLUCOSE MONITORING | ||||||
| 10/08/2020 | Eli Lilly and Company | — | — | In-kind items and services | $1,092.40 | Research |
| Study: A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | ||||||
| 07/31/2020 | Eli Lilly and Company | — | — | In-kind items and services | $142.50 | Research |
| Study: A PHASE 2, PARALLEL, COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS | ||||||
| 07/29/2020 | Ascensia Diabetes Care US Inc. | — | — | Cash or cash equivalent | $54,390.75 | Research |
| Study: Clinical Trial Agreement - CPlus - GCA-PRO-2019-013-01 | ||||||
| 07/28/2020 | Eli Lilly and Company | — | — | In-kind items and services | $1,046.44 | Research |
| Study: RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN | ||||||
| 06/25/2020 | Eli Lilly and Company | — | — | In-kind items and services | $2,337.38 | Research |
| Study: RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF OSTEOARTHRITIS | ||||||
| 06/25/2020 | Eli Lilly Export S.A. Puerto Rico Branch | — | — | In-kind items and services | $790.46 | Research |
| Study: RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN | ||||||
| 05/28/2020 | Ascensia Diabetes Care US Inc. | — | — | Cash or cash equivalent | $2,920.00 | Research |
| Study: Clinical Trial Agreement - CPlus - GCA-PRO-2019-013-01 | ||||||
| 05/20/2020 | Ascensia Diabetes Care US Inc. | — | — | Cash or cash equivalent | $31,250.00 | Research |
| Study: Clinical Trial Agreement - CPlus - GCA-PRO-2019-013-01 | ||||||
| 04/27/2020 | Eli Lilly and Company | — | — | In-kind items and services | $967.94 | Research |
| Study: RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | ||||||
| 04/23/2020 | Ascensia Diabetes Care US Inc. | — | — | Cash or cash equivalent | $79,680.58 | Research |
| Study: Clinical Trial Agreement - TV4 - GCA-PRO-2019-006-01 | ||||||
| 03/12/2020 | Ascensia Diabetes Care US Inc. | — | — | Cash or cash equivalent | $38,598.56 | Research |
| Study: Clinical Trial Agreement - TV4 - GCA-PRO-2019-006-01 | ||||||
| 03/05/2020 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $83.30 | General |
| 03/05/2020 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $44.20 | General |
| 03/05/2020 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $23.80 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Clinical Trial Agreement - TV4 - GCA-PRO-2019-006-01 | Ascensia Diabetes Care US Inc. | $118,279 | 2 |
| Clinical Trial Agreement - CPlus - GCA-PRO-2019-013-01 | Ascensia Diabetes Care US Inc. | $88,561 | 3 |
| Clinical Trial Agreement - CTX - GCA-PRO-2020-004-01 | Ascensia Diabetes Care US Inc. | $85,570 | 1 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP, IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC, IN ADULTS WITH TYPE 1 DIABETES PRONTO-T1D | Eli Lilly and Company | $67,029 | 3 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO, BOTH IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC IN ADULTS WITH TYPE 2 DIABETES PRONTO-T2D | Eli Lilly and Company | $23,319 | 3 |
| A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $3,050 | 1 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF OSTEOARTHRITIS | Eli Lilly and Company | $2,337 | 1 |
| RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | Eli Lilly and Company | $1,704 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) | Eli Lilly and Company | $1,407 | 1 |
| A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | Eli Lilly and Company | $1,392 | 2 |
| A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO IN PARTICIPANTS WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES | Eli Lilly and Company | $1,078 | 1 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN | Eli Lilly and Company | $1,046 | 1 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | Eli Lilly and Company | $967.94 | 1 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN | Eli Lilly Export S.A. Puerto Rico Branch | $790.46 | 1 |
| A STUDY OF LY900014 IN PARTICIPANTS WITH TYPE 2 DIABETES USING CONTINUOUS GLUCOSE MONITORING | Eli Lilly and Company | $603.06 | 1 |
| A PHASE 3 MULTICENTER RANDOMIZED PARALLEL-DESIGN OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) | Eli Lilly and Company | $430.65 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | Eli Lilly and Company | $386.00 | 1 |
| A PHASE 2, PARALLEL, COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $142.50 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | Eli Lilly and Company | $99.32 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | Eli Lilly and Company | $49.59 | 1 |
| A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, 18-WEEK TRIAL OF INVESTIGATIONAL DULAGLUTIDE DOSES VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES ON METFORMIN MONOTHERAPY | Eli Lilly and Company | $9.69 | 1 |
About Dr. Leslie Klaff, MD
Dr. Leslie Klaff, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Renton, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1720009764.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Leslie Klaff, MD has received a total of $551,260 in payments from pharmaceutical and medical device companies, with $148,669 received in 2023. These payments were reported across 74 transactions from 4 companies. The most common payment nature is "" ($546,341).
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Renton, WA
- Active Since 07/23/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1720009764
Products in Payments
- CONTOUR NEXT ONE Meter (Device) $11.15
- TRULICITY (Drug) $9.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Renton
Ronald Brazg, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $429,781
Endocrinology, Diabetes & Metabolism $429,781
Ramona Pungan, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $2,672
Endocrinology, Diabetes & Metabolism $2,672
Wenyi Zhang, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $734.52
Endocrinology, Diabetes & Metabolism $734.52
Theresa Tran, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $255.49
Endocrinology, Diabetes & Metabolism $255.49
Allen Sussman, Md, MD
Endocrinology, Diabetes & Metabolism
Endocrinology, Diabetes & Metabolism